HL Pharma is pleased to announce that it is the Sponsor and Distributor of Lymphoseek. Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.
HL Pharma is pleased to announce it is partnering with Novartis Australia to supply one of their ophthalmic products under The Special Access Scheme or Authorised Prescriber Scheme. This is until the Australian registered product becomes available.
Glanatec (ripasudil) 0.4% Eye Drops Ripasudil is a Rho Kinase inhibitor, licensed in Japan. This product is not registered in Australia and is available for supply under The Special Access Scheme (SAS) C
A Section 19a approval is no longer available for the supply Dexafree. Dexafree continues to be available under SAS C if required. Please contact us to find out more about information on this product.